GlassScriptPhysician profile
Yohena Hernandez-Clemente
NPI 1780375154
$2,559.78
in general payments reported to CMS, 2019-2025
16 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $382 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.64 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $519.50 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $252.40 | 2025 | Dupixent |
| Grifols USA, LLC | $236.03 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $222.37 | 2024-2025 | |
| Csl Behring | $186.91 | 2025 | Andembry, Hizentra |
| Novartis Pharmaceuticals Corporation | $178.88 | 2025 | |
| Greer Laboratories, INC. | $166.24 | 2025 | Oralair |
| Amgen INC. | $153.28 | 2024-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $148.02 | 2025 | Takhzyro, Cuvitru |
| Pharming Healthcare, INC. | $138.09 | 2024-2025 | Ruconest |
| Glaxosmithkline, LLC. | $130.70 | 2024-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $88.85 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $48.04 | 2025 | Orladeyo |
| Alk-Abello, INC | $47.43 | 2025 | Grastek, Ragwitek, Odactra |
| Ionis Pharmaceuticals, INC. | $27.42 | 2025 | Dawnzera |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $15.62 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yohena Hernandez-Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.